Xue Shao

Xue Shao

Auto-generated profile, based on publicly available information

Xue Shao

Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2020 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
HHHisashi Hidaka
Hisashi Hidaka
HUHaruki Uojima
Haruki Uojima
TNTakahide Nakazawa
Takahide Nakazawa
XSXue Shao
Xue Shao
YHYusuke Hara
Yusuke Hara
WKWasaburo Koizumi
Wasaburo Koizumi

22 November 2021 in Digestive Diseases
Verified
Journal Article
Open access
PDF file
XSXue Shao
Xue Shao
HUHaruki Uojima
Haruki Uojima
TATaeang Arai
Taeang Arai
YOYuji Ogawa
Yuji Ogawa
TSToru Setsu
Toru Setsu
WKWasaburo Koizumi
Wasaburo Koizumi
Background: Data regarding the influence of patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism for patients with liver cirrhosis (LC) are scarce. Objective: This study assesses the role of the PNPLA3 polymorphism for the development of LC and its complications by the findings of genetic examinations. Methods: Patients with LC caused by virus (n = 157), alcohol (n = 104), nonalcoholic fatty liver disease (NAFLD) (n = 106), or autoimmune disease (n = 33) and without LC (n = 128) were enrolled. LC was composed of the presence and absence of complications, such as variceal bleeding, hepatic ascites, and hepatic encephalopathy. To assess the role of the PNPLA3 polymorphism, odds ratio (OR) for the rs738409 variant was calculated for the patients between (i) with LC and without LC in the entire cohort and (ii) the presence and absence of complications in the patients with LC. Results: There was a significant difference among the patients without LC and those with alcohol, NAFLD-related LC in the frequency of G alleles (p < 0.001, both). According to complications of LC, the OR for NAFLD-related cirrhosis significantly increased in the presence of the two mutated alleles (OR = 3.165; p = 0.046) when the wild type was used as the reference. However, there were no significant risks for the complications in the virus and alcohol-related cirrhosis unless there was a presence of G alleles. Conclusion: The PNPLA3 polymorphism was associated with the risk of NAFLD-related LC and its complications.

6 August 2020 in Digestive Diseases
Verified
Journal Article
Open access
PDF file
NWNaohisa Wada
Naohisa Wada
HUHaruki Uojima
Haruki Uojima
TSTakashi Satoh
Takashi Satoh
SOSosei Okina
Sosei Okina
SIShuichiro Iwasaki
Shuichiro Iwasaki
WKWasaburo Koizumi
Wasaburo Koizumi
Background: To make an accurate estimate of the response to thrombopoietin (TPO) receptor agonists for thrombocytopenia associated with chronic liver disease, we evaluated the influence of antiplatelet autoantibodies on the response to lusutrombopag in thrombocytopenic patients with liver disease. Methods: A prospective study was conducted at 2 hospitals. Thrombocytopenic patients with liver disease received oral lusutrombopag 3.0 mg once daily for up to 7 days. We analyzed changes in platelet counts from baseline to the maximum platelet count on days 9–14. The definition of clinical response was a platelet count of ≥5 × 104/μL with an increased platelet count of ≥2 × 104/μL from baseline. We assessed the correlation between the response to treatment drug and antiplatelet autoantibodies measured by anti-GPIIb/IIIa antibody-producing B cells. Results: Thirty patients received the trial drug. There were 25 responders and 5 nonresponders. The median change in platelet counts was 3.9 × 104/μL (95% CI 2.8–4.6, p < 0.0001). The correlation between change in platelet counts and the frequency of the anti-glycoprotein IIb/IIIa antibody-producing B cells was moderate (r = 0.414, 95% CI 0.064–0.674, p = 0.023). In multivariate analysis of factors affecting the change in platelet counts, the anti-GPIIb/IIIa antibody-producing B cells were identified as an independent factor (regression coefficient [B] = 0.089; CI 0.021–0.157, p = 0.013). Conclusion: Anti-GPIIb/IIIa antibody-producing B cells may be a predictor for TPO receptor agonists in patients with chronic liver disease.

28 June 2021 in Digestive Diseases
Verified
Journal Article
Open access
PDF file
KKKousuke Kubota
Kousuke Kubota
HUHaruki Uojima
Haruki Uojima
XSXue Shao
Xue Shao
SIShuichiro Iwasaki
Shuichiro Iwasaki
HHHisashi Hidaka
Hisashi Hidaka
WKWasaburo Koizumi
Wasaburo Koizumi
Background: Data regarding the additional effect on the recurrence of hepatic encephalopathy (HE) after oral L-carnitine administration are scarce. Objective: This study aimed to assess the additional effects of L-carnitine in patients who were receiving rifaximin for HE. Methods: This randomized study comprised a screening visit and a 12-week treatment period. Patients who fulfilled the eligibility criteria were randomized to either group A (additional rifaximin) or group B (additional L-carnitine and rifaximin). Group A received 1,200 mg/day of rifaximin. Group B received 1,500 mg/day of L-carnitine and rifaximin at 1,200 mg/day. The endpoints were the changes in the portal systemic encephalopathy (PSE) index and the admission rate from the baseline for the duration of the study in both groups. Results: Eighty-three patients were randomized to either group A (n = 42) or group B (n = 41). In group A, the PSE index decreased from 0.35 ± 0.09 at baseline to 0.27 ± 0.11 on the final evaluation day (p = 0.001). In group B, the PSE index decreased from 0.37 ± 0.09 at baseline to 0.24 ± 0.11 on the final evaluation day (p = 0.001). Although there was not a significant reduction in the PSE index in group A compared to that in group B (p = 0.202), the admission rates were 30.9% and 9.8% in groups A and B, respectively. Additional L-carnitine significantly reduced the admission rate (p = 0.028). Conclusion: L-Carnitine addition reduced the risk of hospitalization for patients who received rifaximin for HE.

24 August 2020 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
HHHisashi Hidaka
Hisashi Hidaka
STSatoshi Tanabe
Satoshi Tanabe
HUHaruki Uojima
Haruki Uojima
XSXue Shao
Xue Shao
SIShuichiro Iwasaki
Shuichiro Iwasaki
WKWasaburo Koizumi
Wasaburo Koizumi